Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease
- 1 January 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (1) , 15-18
- https://doi.org/10.1200/jco.2004.10.910
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?Journal of Clinical Oncology, 2004
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003
- Hodgkin's Disease — Clinical Trials and TravailsNew England Journal of Medicine, 2003
- Involved-Field Radiotherapy for Advanced Hodgkin's LymphomaNew England Journal of Medicine, 2003
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 2003
- To the EditorJournal of Clinical Oncology, 2003
- ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trialAnnals of Oncology, 2002
- The achievements of the EORTC Lymphoma GroupEuropean Journal Of Cancer, 2002
- 77 Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease six-year results of the EORTC-GPMC controlled clinical trials ‘H7-VF’, ‘H7-F’ and ‘H7-U’International Journal of Radiation Oncology*Biology*Physics, 1997
- Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trialAnnals of Oncology, 1997